KMDA
Kamada Ltd.
KMDA has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over KMDA overall, supported by stronger fundamentals and stronger valuation.
KMDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
KMDA's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
KMDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $5.76 | -29% |
| Forward | 18x | $8.13 | — |
| Fair | 21x | $7.96 | -2.1% |
| Current | 21x | $8.13 | — |
| Expensive | 38x | $14.26 | +75% |
Historical ranges are pointers, not guarantees.
KMDA's PE is in its fair range at 21x. On analysts' estimates for next year's earnings, today's price would be 18x, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over KMDA in the historical PE scenario, which offers more potential upside but is not a forecast.
KMDA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect KMDA's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over KMDA on the outlook, with more favorable earnings and profitability expectations.
KMDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.45 | +18% |
| Q2 2026 | $0.38 | +15% |
| Q1 2026 | $0.35 | +25% |
| Q4 2025 | $0.35 | +40% |
| Q3 2025 | $0.35 | +25% |
| Q2 2025 | $0.33 | +22% |
| Q1 2025 | $0.28 | +22% |
| Q4 2024 | $0.25 | +67% |
| Q3 2024 | $0.28 | +133% |
KMDA has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
KMDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $54.9M | +23% |
| Q1 2026 | $45.2M | +2.8% |
| Q4 2025 | $44.7M | +15% |
| Q3 2025 | $47M | +13% |
| Q2 2025 | $44.8M | +5.4% |
| Q1 2025 | $44M | +17% |
| Q4 2024 | $39M | +7.1% |
| Q3 2024 | $41.7M | +10% |
KMDA's revenue has grown year over year for 10 quarters in a row: $55M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 17% | +1.5 points |
| Q1 2026 | 15% | -2.3 points |
| Q4 2025 | 8% | -5.1 points |
| Q3 2025 | 17% | +3.9 points |
| Q2 2025 | 16% | +2.5 points |
| Q1 2025 | 18% | +7 points |
| Q4 2024 | 13% | +5.4 points |
| Q3 2024 | 13% | +1.2 points |
KMDA has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over KMDA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
KMDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $16M | +166% |
| Q1 2026 | -$1.3M | +$717K |
| Q4 2025 | $5M | -34% |
| Q3 2025 | $6.8M | -66% |
| Q2 2025 | $6M | -45% |
| Q1 2025 | -$2M | -$319K |
| Q4 2024 | $7.5M | +207% |
| Q3 2024 | $20.1M | +$20.9M |
KMDA generated $26M in free cash flow over the past year, down 16% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over KMDA on cash flow, with more consistent year-over-year improvement.
KMDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.9% | -1.1M shares |
| 1 year | +2% | +1.1M shares |
| 3 years | +29% | +13.1M shares |
| 5 years | +24% | +11M shares |
| Available history | +39% | +16.3M shares |
KMDA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q3 2024 | — |
| Q2 2024 | — |
KMDA hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
KMDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -1.9x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
| Q3 2024 | -2.1x | Net Cash |
KMDA has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over KMDA on leverage, with a lower net debt burden relative to earnings.
KMDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.1 | Neutral |
| Stochastic | 41.1 | Neutral |
KMDA's weekly RSI is 53 (neutral) and its Stochastic is 41 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
KMDA PE vs Healthcare Sector
| Metric | KMDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 17% below |
| PE % | 52 | 29 | 23 pts above |
KMDA is trading at 21x earnings, a 17% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over KMDA on valuation relative to its sector.
KMDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.96 | 2.1% above |
| 20 week MA | $7.81 | 4.1% above |
| 50 week MA | $7.91 | 2.8% above |
| 100 week MA | $7.44 | 9.3% above |
| 200 week MA | $6.36 | 28% above |
KMDA is in an uptrend: it's above all five of its weekly moving averages, and 28% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
KMDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.84 | $6.60 | -3.5% |
| 2021 | $6.60 | $6.78 | +2.7% |
| 2022 | $6.78 | $3.92 | -42% |
| 2023 | $3.92 | $6.12 | +56% |
| 2024 | $6.12 | $5.92 | -3.3% |
| 2025 | $5.92 | $7.07 | +19% |
| 2026 YTD | $7.07 | $8.13 | +15% |
KMDA has finished lower in three of the last six years. It's up 15% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over KMDA on returns for 2026, with the stronger performance.